[Fosun Pharma: Fosun Pharmaceutical Industry intends to acquire 50% equity of Fosun Kite for US$27 million, and plans to increase its capital by US$10 million in the future] Jinshi Data reported on September 13 that Fosun Pharma announced that its holding subsidiary Fosun Pharmaceutical Industry signed an "Equity Transfer Agreement" with Kite Pharma and Fosun Kite. Fosun Pharmaceutical Industry intends to invest US$27 million in cash to acquire 50% equity of Fosun Kite held by Kite Pharma. After the completion of this transfer, Fosun Pharmaceutical Industry intends to become the sole shareholder of Fosun Kite and increase its capital by US$10 million in cash or RMB equivalent. The relevant capital increase funds will be used to support Fosun Kite's subsequent product development and operation. Fosun Kite and Kite Pharma have reached an Amended and Restated License Agreement, according to which Fosun Kite has been licensed by Kite Pharma to exclusively develop, produce and commercialize Axi-Cel (i.e. Fosun Kite's marketed product "Yikaida") and Brexu-Cel (i.e. Fosun Kite's research project FKC889) in the region (i.e. China, Hong Kong and Macau) and field (cancer treatment) and use the agreed proprietary technology for commercialization purposes. (Reprinted from: Jinshi Data)